Navigation Links
NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
Date:5/28/2008

SOPHIA ANTIPOLIS, France, May 28 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced the completion of patient enrollment in the third pivotal phase 3 clinical trial for naproxcinod, in patients with osteoarthritis of the hip (the 303 study). 810 patients have been randomized in 120 clinical centers in North America and Europe in this study, which is the final phase 3 trial in NicOx' clinical plan for the regulatory filing of naproxcinod. The objective of this study is to assess naproxcinod's efficacy in relieving the signs and symptoms of osteoarthritis of the hip and provide additional safety data, including further information on naproxcinod's blood pressure profile in comparison to another anti-inflammatory medication. Results from this study are expected in Q4 2008 and NicOx projects the filing of a New Drug Application (NDA) in mid-2009.

NicOx is currently in the final stages of developing naproxcinod as an investigational drug for treating the signs and symptoms of osteoarthritis. Naproxcinod is the most advanced compound in a novel class of anti-inflammatory agents known as the Cyclooxygenase-Inhibiting Nitric Oxide Donators (CINODs). The 303 study follows the previous two pivotal phase 3 trials. Successful results were obtained in the 301 phase 3 study, in patients with osteoarthritis of the knee (see press release of October 27, 2006). These data demonstrated superior efficacy to placebo. Data collected suggested that naproxcinod could have no detrimental effect on blood pressure, in contrast to naproxen, a widely used non-steroidal anti-inflammatory drug (NSAID). NSAIDs are known to have the tendency to elevate blood pressure to an extent that may increase the rate of serious cardiovascular adverse events, such as heart attack and stroke.

The 302 study for naproxcinod in patients with osteoarthritis of the knee (see press release of April 3, 2007) is due to report results in Q3 2008.

Maarten Beekman, Vice
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
2. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
3. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
4. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
5. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
6. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
7. NicOx Naproxcinod ABPM Data Presented at American Heart Association
8. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
9. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
10. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
11. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... RADNOR, Pa. , Nov. 26, 2014 ... dedicated to the development of innovative transdermal synthetic cannabinoid ... the Piper Jaffray 26th Annual Healthcare Conference 2014. The ... the New York Palace in New York ... , will present at 4:50 pm on Tuesday, December ...
(Date:11/26/2014)... -- According to the new research ... Battery, Pneumatic), by Product (Drill, Saw, Stapler, Reamer, ... (Orthopedic, ENT, Oral, Thoracic, Neurology) - Global Forecasts ... Instruments Market is estimated to be worth around ... expected to grow at a moderate CAGR during ...
(Date:11/26/2014)... , Nov. 25, 2014 Nanomix ... on the development of mobile diagnostic tests ... in hospital and pre-hospital settings, today announced ... 13485:2003 certification.  The certification was awarded by ... the world,s leading certification bodies. ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Nanomix Receives ISO 13485:2003 Certification 2
... 4, 2011 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... North America beyond physician offices and outpatient clinics with the ... and reference laboratories. The new line is expected to be ... regulatory approval and other requirements. Roche Diagnostics ...
... CLEMENTE, Calif., Oct. 4, 2011 ReShape Medical®, Inc. ... and chief executive officer.  Interim CEO, Ken Charhut, will ... chairman of the board for ReShape Medical.   ... and CEO of Luminous Medical, Inc., an innovative glucose ...
Cached Medicine Technology:Roche to Expand Coagulation Testing Portfolio, Develop New Systems for Diagnostic Laboratories in US and Canada by 2014 2ReShape Medical Names Richard Thompson President and Chief Executive Officer 2
(Date:11/27/2014)... Ericdress.com today announced a site-wide ... to 85% off, on all its clothing, shoes and other ... 1 – 7, 2014 only. , At the special offer, ... above $109 can enjoy an extra $10 discount. Moreover, orders ... business specially recommended its new collection of 2015 evening dresses ...
(Date:11/27/2014)... As everyone knows, Cyber Monday is a crazy shopping ... Tidebuy is now providing many big promotions on its ... 15% of the current prices. The discount are up to ... free shipping (for orders above $88) from Dec. 1 – ... and more people are willing to shop on the internet. ...
(Date:11/27/2014)... 28, 2014 Recently, DressVe , the ... Cyber Monday Sales, which are valid during Nov. 29 – ... available on these new dresses, up to 90% off. In ... Click to view more at http://www.dressve.com/ , Dresses ... a great way to showcase somebody’s personality and figure. The ...
(Date:11/27/2014)... 2014 The report “Blepharitis – ... the therapeutic development for Blepharitis, complete with comparative ... target, mechanism of action (MoA), route of administration ... and featured news and press releases. It also ... for Blepharitis and special features on late-stage and ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 TORQ Cycle is ... professional instructors who go out of the way to help ... people to get fit and do their workouts sincerely using ... they understand the fact that it is important for people ... past year, they have made sure that people take to ...
Breaking Medicine News(10 mins):Health News:Ericdress.com Special Monday Sales Are Ready For Everyone 2Health News:Tidebuy.com Launching Overcoats Sales for the Special Monday in 2014 2Health News:DressVe.com Introduces Its 2014 Special Monday Sales To The Global Customers 2Health News:Blepharitis Pipeline Market Review on Drugs and Companies H2 2014 2Health News:Blepharitis Pipeline Market Review on Drugs and Companies H2 2014 3Health News:Blepharitis Pipeline Market Review on Drugs and Companies H2 2014 4Health News:The new wave in Fitness : Stay Active with Innovative Indoor Cycling Programs 2
... technology reduces radiation exposure, eliminates workflow complexity, and ... MEDRAD,s Intego(TM) PET Infusion System has been named ... innovative products of the year. The magazine ... readership considers to be the most far-reaching, game ...
... Members Say Patient Care at Risk With Threats ... from three major unions representing more than 3,000 ... Care (ARH) facilities in eastern Kentucky and southern ... of directors to meet with them to discuss ...
... Foundation Health Plan,Inc., Kaiser Foundation Hospitals and their subsidiaries ... quarter ended December 31,2008, compared to $9.6 billion in ... million in the fourth quarter of 2008, compared to ... year. The difference between the two,quarters was primarily ...
... general health, functioning improve , , FRIDAY, Feb. 13 ... lose weight, exercise can improve postmenopausal women,s quality of ... sedentary postmenopausal women (average age 57.4) randomly assigned to ... groups: an exercise expenditure of 4 kilocalories per kilogram ...
... As the FDA and pharmaceutical manufacturers contemplate ... plans for extended release opioids, thousands of clinicians ... discovered a resource that supports the safe and ... in Pain ( www.emergingsolutionsinpain.com ) is a ...
... more to promote awareness, study says , , FRIDAY, Feb. 13 ... name or role -- the doctors assigned to their care, ... "The majority of hospitalized patients we looked at were not ... study author Dr. Vineet Arora, associate program director at the ...
Cached Medicine News:Health News:MEDRAD Molecular Imaging Earns Top Rank in Innovation 2Health News:MEDRAD Molecular Imaging Earns Top Rank in Innovation 3Health News:Health Care Workers Call on ARH Board Members to Meet, Develop Real Strategy to Deal With Hospitals' Bottom Line 2Health News:Health Care Workers Call on ARH Board Members to Meet, Develop Real Strategy to Deal With Hospitals' Bottom Line 3Health News:Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals Report Fourth Quarter and Fiscal-Year 2008 Results 2Health News:Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals Report Fourth Quarter and Fiscal-Year 2008 Results 3Health News:Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals Report Fourth Quarter and Fiscal-Year 2008 Results 4Health News:Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals Report Fourth Quarter and Fiscal-Year 2008 Results 5Health News:Exercise Boosts Quality of Life in Postmenopausal Women 2Health News:Opioid Safety and Efficacy Web Resource for Clinicians Supports Education and Practice Needs 2Health News:Opioid Safety and Efficacy Web Resource for Clinicians Supports Education and Practice Needs 3Health News:Many Hospital Patients Can't ID Their Doctors 2Health News:Many Hospital Patients Can't ID Their Doctors 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: